Polymers containing polysaccharides such as alginates or modified alginates

• US 6,642,363 B1
• Filed: 05/03/1999
• Issued: 11/04/2003
• Est. Priority Date: 09/19/1996
• Status: Expired due to Term

• Current Assignee: University of Alabama (University of Alabama System)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Bouhadir, Kamal H., Rowley, Jon A., Wong, Wai Kung, Mooney, David J.
• Primary Examiner(s): Wilson, James O.
• Assistant Examiner(s): White, Everett
• Application Number:
  US09/147,900
• Time in Patent Office: 1,646 Days
• Field of Search: 536/3, 536/124, 514/2, 514/54
• US Class Current: 536/3
• CPC Class Codes: A61K 35/34 Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes vascular smooth muscle A61K35/44
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: A61K 47/61 the organic macromolecular compound being a polysaccharide or a derivative thereof
• CPC Class Codes: A61L 2300/232 Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
• CPC Class Codes: A61L 2300/25 Peptides having up to 20 amino acids in a defined sequence
• CPC Class Codes: A61L 2300/252 Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• CPC Class Codes: A61L 2300/254 Enzymes, proenzymes
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 27/20 Polysaccharides
• CPC Class Codes: A61L 27/3839 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: A61L 27/3847 Bones
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/58 Materials at least partially resorbable by the body
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07H 13/02 by carboxylic acids
• CPC Class Codes: C08B 37/0084 Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
• CPC Class Codes: C08G 81/00 Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers involving only carbon-to-carbon unsaturated bond reactions C08F299/00 ; polyester-amides C08G69/44; polyester-imides C08G73/16; polyamides-imides C08G73/14; block- or graft polymers containing polysiloxane sequences C08G77/42
• CPC Class Codes: C08G 83/003 Dendrimers
• CPC Class Codes: C08L 5/04 Alginic acid; Derivatives thereof

Abstract

Materials which contain polysaccharide chains, particularly alginate or modified alginate chains. The polysaccharide chains may be included as side chains or auxiliary chains from a backbone polymer chain, which may also be a polysaccharide. Further, the polysaccharide chains may be cross-linked between side chains, auxiliary chains and/or backbone chains. These materials and non-modified or otherwise modified alginate materials are advantageously modified by covalent bonding thereto of a biologically active molecule for cell adhesion or other cellular interaction. Processes for preparation of these alginate materials and methods for using them, particularly for cell transplantation and tissue engineering applications.

Claims

1. A modified alginate, which comprises at least one alginate chain section to which is bonded by covalent bonding at least one cell attachment peptide or RGD peptide which promotes cell adhesion and growth.

2. The modified alginate of claim 1, wherein the molecule useful for cell adhesion and growth is bonded through a uronic acid residue on the alginate chain section.

3. The modified alginate of claim 1, wherein the alginate chain section comprises an oligomeric block unit of D-mannuronate, an oligomeric block unit of L-guluronate, an oligomeric block unit of D-mannuronate and L-guluronate or a mixture of said block units.

4. The modified alginate of claim 1, wherein the alginate chain section has a molecular weight of less than about 50,000.

5. The modified alginate of claim 1, wherein the alginate chain section has a molecular weight of less than about 30,000.

6. The modified alginate of claim 1, wherein the alginate chain section has a molecular weight of about 100,000 or more.

7. The modified alginate of claim 1, wherein the alginate chain section is a naturally occurring alginate.

8. A modified alpinate of claim 1, wherein the modified alginate contains at least one alginate chain sectiononded to a polymeric backbone section or at least one alginate chain section crosslinked to another alginate chain section on the same or a different molecule.

9. A method for cell transplantation into a system which comprises implanting a modified alginate of claim 8 in a matrix form into the system and subsequently introducing the cells for transplantation into the matrix.

10. A method for treating a human or animal which comprises administering thereto a modified alginte of claim 8, as a matrix for bone or soft tissue replacement.

11. A method for drug delivery which comprises administering to a human or animal a modified alginate of claim 1, wherein the molecule useful for cellular adhesion and growth is a drug and it is bonded to the at least one alginate chain section by a biodegradeable bond.

12. An aqueous composition containing an alginate material of claim 1 and water.

13. An injectable solution for forming cell transplantation matrices comprising a modified alginate, which comprises at least one alginate chain section to which is bonded by covalent bonding at least one molecule useful for cell adhesion and growth, and viable cells for said transplantation.

14. A transplantation matrix comprising a hydrogel of a modified alginate, which comprises at least one alginate chain section to which is bonded by covalent bonding at least one molecule useful for cell adhesion and growth, and viable cells for said transplantation.

15. A method for cell transplantation comprising administering a mixture of a modified alginate, which comprises at least one alginate chain section to which is bonded by covalent bonding at least one molecule useful for cell adhesion and growth, and cells for transplantation.

16. A polymer comprising,

(a) a polymeric backbone section,

(b) a side chain comprising polymerized D-mannuronate monomers, L-guluronate monomers or both D-mannuronate and L-guluronate monomers bonded to said backbone, optionally through a linker, and

(c) a biologically active molecule useful for cell adhesion and growth covalently bonded to the side chain.

17. The polymer of claim 16, wherein the biologically active molecule is bonded through a uronic acid residue on the side chain.

18. The polymer of claim 16, wherein the biologically active molecule is a cell attachment peptide, a peptide growth factor, an enzyme, a proteoglycan or a polysaccharide.

19. The polymer of claim 16, wherein the biologically active molecule is a cell attachment protein.

20. An injectable solution for forming cell transplantation matrices comprising a polymer according to claim 19.

21. An injectable solution of claim 20 further comprising viable cells for said transplantation.

22. A cell transplantation matrix comprising a hydrogel of a polymer according to claim 19 and viable cells for said transplantation.

23. The polymer of claim 16, wherein at least one side chain is bonded through a linker and the linker is a residue of an amino acid, amino aldehyde, amino alcohol, hydrazine, hydrazide or semicarbazide.

24. The polymer of claim 16, wherein the backbone section is a poly(vinyl alcohol), poly(ethylene oxide), polypeptide, poly(amino acid) or poly(uronic acid) polymer section, or modified alginate.

25. The polymer of claim 16, wherein the side chain comprises an oligomeric block unit of D-mannuronate, an oligomeric block unit of L-guluronate, an oligomeric block unit of D-mannuronate and L-guluronate or a mixture of said block units.

26. The polymer of claim 16, having a backbone section with a molecular weight of less than about 50,000.

27. The polymer of claim 26, having side chains each with a molecular weight less than about 50,000.

28. The polymer of claim 16, having a backbone section with a molecular weight above 100,000.

29. The polymer of claim 16, wherein the linker provides a biodegradable bond between the backbone section and the side chain.

30. The polymer of claim 29, wherein the linker is bonded to the polymeric backbone section by an ester group, imine, hydrazone or semicarbazone group.

31. An aqueous composition containing a polymer of claim 16 and water.

32. A polymer comprising,

(a) a polymeric backbone section, and

(b) an alginate side chain, with uronic acid units having carboxylic acid groups, comprising polymerized D-mannuronate monomers, L-guluronate monomers or both D-mannuronate and L-guluronate monomers bonded to said backbone, optionally through a linker,

wherein the polymer comprises multiple side chains wherein at least two of said side chains are crosslinked, the crosslinking being with a polyfunctional crosslinking agent having at least two nitrogen-containing functional groups which covalently bond to the carboxylic acid groups in the uronic acid units of the alginate side chains.

33. An alginate material comprising alginate chains with covalently bonded crosslinking between chains, the crosslinking being with a polyfunctional crosslinking agent having at least two nitrogen-containing functional groups which covalently bond to carboxylic acid groups in uronic acid units of the alginate chains.

34. The alginate material of claim 33, wherein the material is crosslinked to the extent such that it resumes essentially its original size and shape after compression.

35. The alginate material of claim 33, wherein the material additionally is gelled by action of a divalent cation.

36. The alginate material of claim 33, wherein the crosslinking agent contains at least two amine, hydrazide or semicarbazide functional groups, or combinations thereof.

37. The alginate material of claim 36, wherein the crosslinking agent is lysine or an alkyl ester thereof.

38. The alginate material of claim 33, wherein 1 mole % or more based on the moles of carboxylic acid groups on uronic acid units in the alginate chains are crosslinked.

39. The alginate material of claim 33, wherein 1-20 mole % or more based on the moles of carboxylic acid groups on uronic acid units in the alginate chains are crosslinked.

40. The alginate material of claim 33, wherein 5-75 mole % or more based on the moles of carboxylic acid groups on uronic acid units in the alginate chains are crosslinked.

41. The alginate material of claim 33, wherein the material is in a viscous liquid form or swellable gel form.

42. The alginate material of claim 33, wherein the material is in a non-swellable, compression resistant form having shape memory properties.

43. The alginate material of claim 33, wherein the material further contains a molecule exhibiting cellular interaction activity bonded to an alginate chain.

44. The alginate material of claim 43, wherein the molecule is a cell adhesion molecule.

45. The alginate material of claim 44, wherein the cell adhesion molecule is a cell attachment peptide, a peptide growth factor, an enzyme, a proteoglycan attachment peptide sequence, a proteoglycan or other polysaccharide exhibiting cell adhesion.

46. The alginate material of claim 43, wherein the molecule exhibiting cellular interaction activity is bonded by covalent bonding to the alginate chain.

47. A matrix for a cell culture system or for tissue engineering composed of the alginate material of claim 33.

48. A method for tissue engineering which comprises introducing as a matrix for the tissue an alginate material of claim 33 in matrix form.

49. The method of claim 48, wherein the alginate material in matrix form is provided before introduction in a suitable size and shape, is altered in size or shape during introducing and essentially resumes its suitable size and shape after introducing.

50. A method for cell transplantation comprising administering a combination of the alginate material of claim 33 and cells for transplantation.

51. A method for treating a human or animal which comprises administering thereto a modified alginate of claim 33, as a matrix for bone or soft tissue replacement.

52. A polymer comprising,

(a) a polymeric backbone section of a poly(vinyl alcohol), poly(ethylene oxide), polypeptide, poly(amino acid) or poly(uronic acid) polymer,

(b) alginate side chains, with uronic acid units having carboxylic acid groups, comprising polymerized D-mannuronate monomers, L-guluronate monomers or both D-mannuronate and L-guluronate monomers bonded to said backbone, optionally through a linker, and

(c) at least one biologically active molecule bonded through a uronic acid unit on an alginate side chain.

53. The polymer of claim 52, wherein the biologically active molecule is a cell attachment protein, a cell attachment peptide, a peptide growth factor, an enzyme, a proteoglycan or a polysaccharide.